Document 0645
 DOCN  M9590645
 TI    Good results from eye implant study. Clearinghouse, P.O. Box 6003,
       Rockville, MD 20849-6003. 800-458-5231 ext. 5023.
 DT    9509
 SO    Treat Review. 1995 Jan;(no 16):4. Unique Identifier : AIDSLINE
       AIDS/95700312
 AB    Researchers are studying the use of ganciclovir, administered by eye
       implants, for the treatment of CMV retinitis. Participants in a
       1992/1993 study who had received the implant showed no progression of
       the disease while a no-implant comparison group suffered a worsening
       infection. The implants are designed to gradually release the drug over
       several months; implant replacement time is unknown, but replacement
       after 32 weeks is advised. Following implantation, initial blurred
       vision occurred, but normal vision returned within a month. Another
       study revealed that the non-implanted eye of a CMV retinitis patient
       usually became infected, but when subsequently treated with the implant,
       took a positive course. A study comparing different treatments for CMV
       retinitis is enrolling. Participants will be treated either with
       standard IV ganciclovir, a ganciclovir implant with oral ganciclovir, or
       a ganciclovir implant with placebo. Participants must have CMV retinitis
       in one eye. Implants are available from the manufacturer through a
       compassionate use program. For more information, contact The Network at
       (800) 734-7104.
 DE    Cytomegalovirus Retinitis/*DRUG THERAPY  Double-Blind Method  *Drug
       Implants  Human  Placebos  NEWSLETTER ARTICLE  RANDOMIZED CONTROLLED
       TRIAL  CLINICAL TRIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).